SEEK ID: https://seek.lisym.org/people/91
Location:
Germany
ORCID: Not specified
Joined: 12th Feb 2018
Expertise: Not specified
Tools: Not specified

LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP) (Leibniz-Institut für Arbeitsforschung (IfADo)) ; LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF) (Leibniz-Institut für Arbeitsforschung (IfADo)) ; LiSyM network (Leibniz-Institut für Arbeitsforschung (IfADo)) ; LiSyM-Krebs Partnering (Leibniz-Institut für Arbeitsforschung (IfADo)) ; Forschungsnetzwerk LiSyM-Krebs (Leibniz-Institut für Arbeitsforschung (IfADo))
Related items
- Programmes (2)
- Projects (5)
- Institutions (1)
- Investigations (0+2)
- Studies (0+1)
- Data files (0+3)
- Publications (29)
- Presentations (4+1)
- Documents (0+1)
LiSyM-Krebs ist ein nationales Forschungsnetz zur Früherkennung und Prävention von Leberkrebs, das unter Verwendung des systemmedizinischen Forschungsansatzes die komplexen, dynamischen Prozesse der Krankheitsprogression analysiert, um ausgehend von den Erkenntnissen aus dem Forschungsnetz LiSyM die Entstehung von Leberkrebs besser zu verstehen, vorherzusagen und im besten Fall sogar zu verhindern. LiSyM-Krebs setzt die erfolgreichen Forschungsaktivitäten der BMBF-Vorgängerprogramme ...
Projects: LiSyM-Krebs Partnering, Forschungsnetzwerk LiSyM-Krebs, SMART-NAFLD, DEEP-HCC network, C-TIP-HCC network
Web page: https://www.lisym-cancer.org
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
This comprises the whole LiSyM network
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org
Start date: 1st Jan 2016
Organisms: Rattus norvegicus, Rattus rattus, Mus musculus, Homo sapiens
Forschungsnetzwerk zur Früherkennung und Prävention- LiSyM-Krebs
Ein Netzwerk von Klinikern, Wissenschaftlern und Datenmanagern hat sich zur Aufgabe gemacht, Methoden zu entwickeln, um Patienten mit einem hohen Risiko für ein Leberkarzinom frühzeitig, in Vorstadien der Tumorentwicklung, identifizieren zu können. Gemeinsam bilden sie das „Systemmedizinische Forschungsnetzwerk zur Früherkennung und Prävention von Leberkrebs“, LiSym-Krebs, das vom Bundesministerium für Bildung und Forschung ...
Programme: LiSyM-Krebs - Systemmedizinisches Forschungsnetz zur Früherkennung und Prävention von Leberkrebs
Public web page: Not specified
Organisms: Homo sapiens
This generic project is intended to be a forum for all LiSyM partner and external stakeholders interested in participating in the BMBF initiative LiSyM-Krebs.
Programme: LiSyM-Krebs - Systemmedizinisches Forschungsnetz zur Früherkennung und Prävention von Leberkrebs
Public web page: https://www.ptj.de/projektfoerderung/gesundheitsforschung/lisym-krebs
Organisms: Not specified
In chronic diseases, at some point the liver can suddenly stop functioning. This is called acute-on-chronic liver failure, or ACLF. This is the leading cause of death in liver patients and is often provoked by the use of transcription or freely available drugs or alcohol abuse. For this condition we need an effective treatment quickly. LiSyM-Pillar III researches the factors that contribute significantly to ACLF. What exactly happens then? Are there any early signs that would enable ACLF to be ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Homo sapiens, Mus musculus, Rattus norvegicus, Rattus rattus
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions. LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Mus musculus, Rattus rattus, Rattus norvegicus, Homo sapiens
Abstract
Authors: Christian H. Holland, Ricardo O. Ramirez Flores, Maiju Myllys, Reham Hassan, Karolina Edlund, Ute Hofmann, Rosemarie Marchan, Cristina Cadenas, Jörg Reinders, Stefan Hoehme, Abdel‐latif Seddek, Steven Dooley, Verena Keitel, Patricio Godoy, Brigitte Begher‐Tibbe, Christian Trautwein, Christian Rupp, Sebastian Mueller, Thomas Longerich, Jan G. Hengstler, Julio Saez‐Rodriguez, Ahmed Ghallab
Date Published: 28th Aug 2021
Publication Type: Journal
DOI: 10.1002/hep4.1797
Citation: Hepatol Commun,hep4.1797
Abstract
Authors: Nachiket Vartak, Dirk Drasdo, Fabian Geisler, Tohru Itoh, Ronald P.J. Oude Elferink, Stan F.J. van de Graaf, John Chiang, Verena Keitel, Michael Trauner, Peter Jansen, Jan G Hengstler
Date Published: 23rd Jun 2021
Publication Type: Journal
DOI: 10.1002/hep.32027
Citation: Hepatology,hep.32027
Abstract (Expand)
Authors: A. Mohs, T. Otto, K. M. Schneider, M. Peltzer, M. Boekschoten, C. H. Holland, C. A. Hudert, L. Kalveram, S. Wiegand, J. Saez-Rodriguez, T. Longerich, J. G. Hengstler, C. Trautwein
Date Published: 22nd Dec 2020
Publication Type: Journal
PubMed ID: 33342543
Citation: J Hepatol. 2021 Mar;74(3):638-648. doi: 10.1016/j.jhep.2020.09.037. Epub 2020 Oct 24.
Abstract (Expand)
Authors: Antje Mohs, Tobias Otto, Kai Markus Schneider, Mona Peltzer, Mark Boekschoten, Christian H. Holland, Christian A. Hudert, Laura Kalveram, Susanna Wiegand, Julio Saez-Rodriguez, Thomas Longerich, Jan G. Hengstler, Christian Trautwein
Date Published: 1st Oct 2020
Publication Type: Journal
DOI: 10.1016/j.jhep.2020.09.037
Citation: Journal of Hepatology,S0168827820336953
Abstract (Expand)
Authors: Nachiket Vartak, Georgia Guenther, Florian Joly, Amruta Damle‐Vartak, Gudrun Wibbelt, Jörns Fickel, Simone Jörs, Brigitte Begher‐Tibbe, Adrian Friebel, Kasimir Wansing, Ahmed Ghallab, Marie Rosselin, Noemie Boissier, Irene Vignon‐Clementel, Christian Hedberg, Fabian Geisler, Heribert Hofer, Peter Jansen, Stefan Hoehme, Dirk Drasdo, Jan G. Hengstler
Date Published: 19th Jun 2020
Publication Type: Journal
DOI: 10.1002/hep.31422
Citation: Hepatology,hep.31422
Poster at SBMC 2018
Creators: Lars Ole Schwen, Lars Kuepfer, Ahmed Ghallab, Jan Hengstler, Tobias Preusser, Raymond Reif
Submitter: Lars Ole Schwen